Max International
Healthier Aging With Clinically Proven Cellular Enhancement Technology
Overview
Raised: $23,359
2023
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
High
Low
Summary Profit and Loss Statement
FY 2023 | FY 2022 | |
---|---|---|
Revenue |
$14,603,138 |
$25,464,199 |
COGS |
$5,720,486 |
$6,394,965 |
Tax |
$140,160 |
$-15,642 |
| ||
| ||
Net Income |
$-9,046,641 |
$-6,336,176 |
Summary Balance Sheet
FY 2023 | FY 2022 | |
---|---|---|
Cash |
$1,250,868 |
$1,245,473 |
Accounts Receivable |
$421,530 |
$480,000 |
Total Assets |
$4,831,920 |
$7,865,721 |
Short-Term Debt |
$16,636,594 |
$24,892,670 |
Long-Term Debt |
$167,482 |
$561,413 |
Total Liabilities |
$16,804,076 |
$25,454,083 |
Raise History
Offering Name | Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Max International | 04/30/2025 | Issuance Express | $50,000,000 | $23,359 | Equity - Preferred | Active | RegCF |
No prior online funding rounds.
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual